✦ LIBER ✦

Protocols cookbook for cancer gene therapy

✍ Scribed by Frank Marini

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 31 KB
Volume: 23
Category: Article
ISSN: 0265-9247
DOI: 10.1002/1521-1878(200101)23:1<108::aid-bies1014>3.0.co;2-o

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gene therapy for pancreatic cancer

✍ Shin Takeda; Akimasa Nakao; Koji Miyoshi; Hiroshi Takagi 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB 👁 2 views

It has been approximately 7 years since the introduction of gene therapy. Since conventional procedures such as surgery, chemotherapy, and radiotherapy have had limited therapeutic value for cancer patients, the evolution of gene therapy seems a promising alternative to many researchers and clinicia

Gene therapy for hemophilia

✍ Marinee K. L. Chuah; Desire Collen; Thierry VandenDriessche 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB

Gene therapy for colon cancer with the h

Gene therapy for colon cancer with the herpes simplex thymidine kinase gene

✍ Link, Charles J.; Levy, John P.; McCann, Leisa Z.; Moorman, Donald W. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 1 views

## Background: The suicide gene and prodrug, herpes simplex thymidine kinase (hstk) and ganciclovir (gcv), are now in clinical trials for recurrent malignancies. ## Methods: We evaluated in vitro and in vivo efficacy of hstk gene transfer and gcv treatment of colonic adenocarcinoma in a syngeneic

Cancer Immune Therapy || The TâBody Ap

Cancer Immune Therapy || The TâBody Approach: Towards Cancer ImmunoâGene Therapy

✍ Stuhler, Gernot; Walden, Peter 📂 Article 📅 2002 🏛 Wiley 🌐 German ⚖ 112 KB

Prodrug activation enzymes in cancer gen

Prodrug activation enzymes in cancer gene therapy

✍ Manish Aghi; Fred Hochberg; Xandra O. Breakefield 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB 👁 2 views

Among the broad array of genes that have been evaluated for tumor therapy, those encoding prodrug activation enzymes are especially appealing as they directly complement ongoing clinical chemotherapeutic regimes. These enzymes can activate prodrugs that have low inherent toxicity using both bacteria

Progress in antiangiogenic gene therapy

Progress in antiangiogenic gene therapy of cancer

✍ Andrew L. Feldman; Steven K. Libutti 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

## BACKGROUND. Because tumors require angiogenesis for growth, inhibiting angiogenesis is a promising strategy for treating cancer patients. Although numerous endogenous angiogenesis inhibitors have been discovered, the clinical evaluation of these agents has been hindered by high dose requirement